- Home
- ZG vs PODD Comparison
ZG vs PODD Comparison
Compare ZG & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZG
- PODD
- Stock Information
- Founded
- ZG 2004
- PODD 2000
- Country
- ZG United States
- PODD United States
- Employees
- ZG N/A
- PODD N/A
- Industry
- ZG Business Services
- PODD Medical/Dental Instruments
- Sector
- ZG Consumer Discretionary
- PODD Health Care
- Exchange
- ZG Nasdaq
- PODD Nasdaq
- Market Cap
- ZG 17.1B
- PODD 16.5B
- IPO Year
- ZG 2011
- PODD 2007
- Fundamental
- Price
- ZG $74.83
- PODD $275.81
- Analyst Decision
- ZG Buy
- PODD Buy
- Analyst Count
- ZG 22
- PODD 16
- Target Price
- ZG $72.48
- PODD $271.19
- AVG Volume (30 Days)
- ZG 424.7K
- PODD 534.3K
- Earning Date
- ZG 02-11-2025
- PODD 02-20-2025
- Dividend Yield
- ZG N/A
- PODD N/A
- EPS Growth
- ZG N/A
- PODD 235.68
- EPS
- ZG N/A
- PODD 5.74
- Revenue
- ZG $2,156,000,000.00
- PODD $1,983,900,000.00
- Revenue This Year
- ZG N/A
- PODD $23.56
- Revenue Next Year
- ZG N/A
- PODD $18.07
- P/E Ratio
- ZG N/A
- PODD $48.16
- Revenue Growth
- ZG 13.12
- PODD 27.42
- 52 Week Low
- ZG $38.06
- PODD $160.19
- 52 Week High
- ZG $83.67
- PODD $279.77
- Technical
- Relative Strength Index (RSI)
- ZG 57.81
- PODD 61.05
- Support Level
- ZG $66.25
- PODD $260.84
- Resistance Level
- ZG $74.13
- PODD $274.45
- Average True Range (ATR)
- ZG 1.86
- PODD 7.44
- MACD
- ZG 0.34
- PODD 0.65
- Stochastic Oscillator
- ZG 91.76
- PODD 88.34
About ZG Zillow Group Inc.
Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Home Loans, ShowingTime, Follow Up Boss, Aryeo and others.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.